Skip to main content
SpringerLink
Log in

Inaxaplin als potenzielle Therapie der APOL1-assoziierten Nephropathie

Inaxapline as a potential therapy for APOL1-associated nephropathy

  • Nephro molekular
  • Published:
Die Nephrologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aghajan M, Booten SL, Althage M et al (2019) Antisense oligonucleotide treatment ameliorates IFN-gamma-induced proteinuria in APOL1-transgenic mice. JCI Insight 4:

  2. Beckerman P, Bi-Karchin J, Park AS et al (2017) Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med 23:429–438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Egbuna O, Zimmerman B, Manos G et al (2023) Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N Engl J Med 388:969–979

    Article  CAS  PubMed  Google Scholar 

  4. Genovese G, Friedman DJ, Ross MD et al (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329:841–845

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gerstner L, Chen M, Kampf LL et al (2022) Inhibition of endoplasmic reticulum stress signaling rescues cytotoxicity of human apolipoprotein-L1 risk variants in Drosophila. Kidney Int

  6. Johnstone DB, Shegokar V, Nihalani D et al (2012) APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. Plos One 7:e51546

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ma L, Chou JW, Snipes JA et al (2017) APOL1 renal-risk variants induce mitochondrial dysfunction. J Am Soc Nephrol 28:1093–1105

    Article  CAS  PubMed  Google Scholar 

  8. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F et al (2005) Apolipoprotein L‑I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309:469–472

    Article  ADS  CAS  PubMed  Google Scholar 

  9. Pollak MR, Friedman DJ (2023) APOL1 and APOL1-associated kidney disease: a common disease, an unusual disease gene—proceedings of the Henry Shavelle professorship. Glomerular Dis 3:75–87

    Article  PubMed  PubMed Central  Google Scholar 

  10. Reeves-Daniel AM, Depalma JA, Bleyer AJ et al (2011) The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11:1025–1030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik IV, Nephrologie und Allgemeinmedizin, Department für Innere Medizin, Medizinische Fakultät und Universitätsklinikum, Universität Freiburg, Hugstetter Straße 55, 79106, Freiburg, Deutschland

    Konrad Lang &  Tobias Hermle

Authors
  1. Konrad Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tobias Hermle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias Hermle.

Ethics declarations

Interessenkonflikt

K. Lang und T. Hermle geben an, dass kein Interessenkonflikt besteht.

Additional information

Redaktion

Oliver Witzke, Essen

Thimoteus Speer, Frankfurt

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lang, K., Hermle, T. Inaxaplin als potenzielle Therapie der APOL1-assoziierten Nephropathie. Nephrologie (2024). https://doi.org/10.1007/s11560-024-00721-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11560-024-00721-6

Search

Navigation